Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Scott Worswick MD

Scott Worswick MD

Associate Professor of Dermatology; Director of Inpatient Dermatology, University of Southern California & Los Angeles County Hospital, Los Angeles, California

Scott Worswick, MD, is in his fifth year as an associate professor of dermatology at USC and in his eighth year as the director of inpatient dermatology (the first half of this time being spent while previously on faculty at UCLA). While at UCLA, Dr. Worswick served as the associate residency program director, and since being at USC since 2018, he has had the privilege of being co-program director with Dr. Ashley Crew.   

Dr. Worswick derives the greatest joy from his work in teaching and mentoring others, particularly in the inpatient dermatology setting. He has been the recipient of the faculty teaching award three times, and was given the “Exceptional MD of the year” award at UCLA. He actively mentors ~10 medical students per year through USC, the SNMA and formerly at UCLA.

In research, his greatest source of fulfillment has been from a project looking at treatment for SJS/TEN. His team did a cross-institutional collaboration between UCLA and USC comparing outcomes of patients treated with etanercept to those with IVIG. Lately, Dr. Worswick has been working on a multi-institutional prospective trial comparing outcomes of DRESS patients treated with steroids to those treated with cyclosporine. Other research has included projects on pityriasis rubra pilaris, granuloma annulare, calciphylaxis, and dermatologic eduction.


Dr. Worswick has no relevant disclosures.